A combined post hoc analysis of SPRINT and ACCORD suggested similar CV bene ts of intensive BP-lowering therapy in the presence or absence of diabetes.121 ACCORD was not only a BP trial, but it also employed a rather complex study design. The partici- pants were randomized rst to intensive versus less-intensive glycemic control, and then either to intensive versus less- intensive BP control or to the addition of feno brate versus placebo on a background of a statin. The trial of glycemic control was terminated early because of higher all-cause mortality with intensive glycemic control.92 This adverse ef- fect of intensive glycemic control was also demonstrated in the CKD subgroup of ACCORD.119 The ACCORD BP trial reported no statistical interaction between glycemic control and BP control on prespeci ed primary and secondary CV outcomes. However, a more detailed combined analysis of data from ACCORD and SPRINT found that the bene cial effects of intensive SBP control (with both trials targeting <120 mm Hg) on combined CV endpoints and on all-cause mortality were similar in the standard glycemia arm of ACCORD and in SPRINT.122,123 In contrast, intensive SBP control increased CV death, HF, and MI in the intensive glycemia arm. 